2012
April
Wednesday, Apr 04, 2012
Genentech statement on counterfeit drug labeled
as Altuzan (bevacizumab) in the United States.
Genentech statement on counterfeit drug labeled as Avastin® (bevacizumab) in the United States.
2011
April
Thursday, Apr 28, 2011
Genentech statement on CAT trial data published in the New England Journal of Medicine.
2010
October
Wednesday, Oct 06, 2010
Genentech, a member of the Roche Group, announced today that ample supplies of Tamiflu® (oseltamivir phosphate), a prescription antiviral medicine to treat flu, will be widely available at
U.S. pharmacies this flu season.
Genentech, Inc. announced today that it has accepted the recommendation of an independent Data and Safety Monitoring Board (DSMB) to stop enrollment into the MAIN trial, a Phase III clinical study evaluating the efficacy and safety of Avastin® (bevacizumab) when added to Rituxan® (rituximab) plus CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy in patients with Diffuse Large B-Cell Lymphoma (DLBCL).
May
Thursday, May 27, 2010
Genentech, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will discuss the company's two supplemental Biologics License Applications (sBLAs) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer during an advisory committee meeting on July 20, 2010.
2009
November
Friday, Dec 11, 2009
Genentech, Inc. announces study of Avastin® (bevacizumab) in early-stage breast cancer (E5103) will resume enrollment and continue as planned.
March
Monday, Mar 09, 2009
Genentech, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will discuss the company's supplemental Biologics License Application (sBLA) for Avastin® (bevacizumab) for people with previously treated glioblastoma during an advisory committee meeting on March 31, 2009.